|
ImmunoCellular Therapeutics |
|
|
1999 Avenue of the Stars, 11th Floor
Los Angeles, CA 90067 USA
phone:818,992.2907
fax:310.201.4746 |
| Symbol |
IMUC |
| Exchange |
OTC |
| Founded |
2006 |
| Employees |
2 |
|
|
| www.imuc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Cellular-based products to treat cancers and neurodegenerative disorders. |
|
| Management |
| Manish Singh, Ph.D., MBA, President and Chief Executive Officer; John S. Yu, M.D., Chief Scientific Officer and Chairman of the Board; C. Kirk Peacock, Chief Financial Officer; James G. Bender, Ph.D., M.P.H., Vice President, Clinical Development; Jacqueline Brandwynne, President and CEO; Colonel Cowell, Principal; Dr. Jaikaria, Managing director; Dr. Martuza, Chief of Neurosurgery Service; Manish Singh, Ph.D., MBA, President and Chief Executive Officer; John S. Yu, M.D., Chief Scientific Officer and Chairman of the Board |
|
|
|
|
| Keywords |
| cancer, neurodegenerative, neurology, Cancer Antigen Vaccines, immunotherapy |
|
|
|
|
| Description |
|
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. |
|
| Products / Services |
The company’s “off the shelf” therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the first quarter of 2010. IMUC also recently completed a Phase I trial of its dendritic cell-based clinical product candidate for glioblastoma.
IMUC has entered into a research and license option deal with the Roche Group for one of its monoclonal antibodies for the diagnosis and treatment of ovarian cancer and multiple myeloma, that provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications.
IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer.
|
|
| Technology / Differentiation |
| ImmunoCellular Therapeutics has two active immunotherapy product platforms-a cancer stem cell vaccine and a dendritic cell-based vaccine-both of which may be applicable to multiple types of cancer. |
|
|
| Status |
| ImmunoCellular Therapeutics, Ltd is currently seeking licensees or partners for the further development of their Cancer Antigen Vaccines program. |
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
